生物制剂对克罗恩病回肠和结肠内镜愈合的疗效比较
该研究 pooled 分析 4 项临床试验中 299 例中重度克罗恩病患者个体数据,比较阿达木单抗、英夫利西单抗、乌司奴单抗和维得利珠单抗治疗 1 年后的内镜愈合率。结果显示,阿达木单抗和英夫利西单抗的 1 年内镜愈合率优于维得利珠单抗;结肠内镜愈合方面阿达木单抗优于乌司奴单抗。
要点
- 与维得利珠单抗相比,阿达木单抗和英夫利西单抗的 1 年内镜愈合率更高。
- 结肠内镜愈合方面,阿达木单抗优于乌司奴单抗,英夫利西单抗呈相似趋势但未达统计学显著。
- 基线回肠 SES-CD≥3 患者中,各生物制剂 1 年回肠内镜愈合无显著差异。
核心结论
- 在中重度克罗恩病患者中,TNF-α 拮抗剂总体在实现 1 年内镜愈合方面优于维得利珠单抗和乌司奴单抗(事后分析)。
研究设计与样本
- 汇总分析 4 项临床试验中 299 例克罗恩病患者的个体水平数据。
- 采用多变量 logistic 回归模型分析生物制剂与 1 年结局的关系,并校正疾病病程、合并使用皮质类固醇及既往抗 TNF 治疗失败。
主要发现
- 与维得利珠单抗(4/56 [7.1%])相比,阿达木单抗(17/61 [27.9%],校正 OR:5.79,95% CI:1.77-18.95,P=0.004)和英夫利西单抗(39/141 [27.7%],校正 OR:4.59,95% CI:1.48-14.22,P=0.008)的 1 年内镜愈合率更高。
- 维得利珠单抗与乌司奴单抗之间未观察到显著差异;在生物制剂初治患者中观察到相似结果。
- 基线回肠 SES-CD≥3 患者中,各生物制剂 1 年回肠内镜愈合无显著差异;对于大(>0.5 cm)回肠溃疡,英夫利西单抗(20/49 [40.8%])无回肠溃疡率优于维得利珠单抗(2/23 [8.7%],校正 OR:5.39,95% CI:1.03-28.05,P=0.045)。
- 结肠病变方面,与乌司奴单抗(9/31 [29.0%])相比,阿达木单抗(30/48 [62.5%],校正 OR:3.97,95% CI:1.45-10.90,P=0.007)的 1 年结肠内镜愈合率更高,英夫利西单抗呈相似趋势(55/105 [52.4%],校正 OR:2.08,95% CI:0.82-5.27,P=0.121)。
关键数值与推荐
- 完全内镜愈合定义为 SES-CD<3,回肠和结肠内镜愈合分别定义为 SES-CD=0。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本文为事后分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We compared the efficacy of adalimumab, infliximab, ustekinumab, and vedolizumab on the ability to achieve endoscopic healing (EH) after 1 year of therapy in moderate-severe Crohn's disease (CD). METHODS: This was a pooled analysis of patient-level data from 299 patients with CD from 4 clinical trials. Proportions of patients treated with each biologic were compared for achieving 1-year complete EH (Simple Endoscopic Score for CD [SES-CD] <3) and ileal and colonic EH separately (SES-CD = 0). Multivariate logistic regression was used to model the relationship between biologics and 1-year outcomes and adjusted for disease duration, concomitant corticosteroid use, and prior antitumor necrosis factor failure. RESULTS: Compared with vedolizumab (4/56 [7.1%]), adalimumab (17/61 [27.9%], adjusted odds ratio [OR]: 5.79, 95% confidence interval [CI]: 1.77-18.95, P = 0.004) and infliximab (39/141 [27.7%], aOR: 4.59, 95% CI: 1.48-14.22, P = 0.008) had superior rates of 1-year EH. No significant difference was observed between vedolizumab and ustekinumab. Similar results were observed among biologic-naive patients. Among patients with baseline ileal SES-CD ≥3, no significant differences were observed between biologics for 1-year ileal EH. However, for large (>0.5 cm) ileal ulcers, infliximab (20/49 [40.8%]) had superior rates of no ileal ulcers compared with vedolizumab (2/23 [8.7%], aOR: 5.39, 95% CI: 1.03-28.05, P = 0.045). No other differences were observed. For colonic disease, compared with ustekinumab (9/31 [29.0%]), adalimumab (30/48 [62.5%], aOR: 3.97, 95% CI: 1.45-10.90, P = 0.007) had superior rates of 1-year EH in the colon, with similar trends observed for infliximab (55/105 [52.4%], aOR: 2.08, 95% CI: 0.82-5.27, P = 0.121). No other differences were observed. DISCUSSION: In this post hoc analysis, TNF-α antagonists were overall superior to vedolizumab and ustekinumab for achieving 1-year EH in moderate-severe CD patients.
引用
- Narula N, Wong ECL, Dulai PS, et al. Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease. Am J Gastroenterol. 2022. PMID: 35435862. doi:10.14309/ajg.0000000000001795
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。